Personalis, Inc. - Common Stock (NQ:PSNL)

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)

September 23, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

Performance

52-Week Range 15.3% below 52-week high

16.00

4.9652W Low 18.8952W High

1 Week 3.5% below 1-week high

15.681W Low 16.581W High

Personalis, Inc. - Common Stock (PSNL) traded between $4.96 and $18.89 over the past 52 weeks and last traded at $16.00, 15.3% below its 52-week high. Over the past week it ranged between $15.68 and $16.58.

Past 12 Months

-1.7%

-3.6%

+9.2%

+162.7%

+103.8%

+84.3%

1W -$0.28

1M -$0.60

3M +$1.35

6M +$9.91

YTD +$8.15

1Y +$7.32

PSNL was +84.3% over the past year, +162.7% over six months, +103.8% year to date, -1.7% in the last week.

12 Months vs Market

PSNL

+84.3%

DIA

+10.7%

SPY

+15.7%

QQQ

+22.9%

IWM

+13.1%

Over the past 12 months PSNL returned +84.3% versus DIA (Dow) +10.7%, SPY (S&P 500) +15.7%, QQQ (Nasdaq 100) +22.9% and IWM (Russell 2000) +13.1%.

Volume & Liquidity 0.52× 3-mo avg

Today 1,835,896 3-mo avg 3.6M

2.8M

2.2M

3.6M

3.3M

YTD

2.6M

2.4M

PSNL most recently traded 1,835,896 shares against a 3-month average daily volume of 3.6M.

More News

September 09, 2026

September 03, 2026

Halper Sadeh LLC is Investigating Whether UTZ, PSNL, DSGR are Obtaining Fair Deals for their Shareholders

August 07, 2026

Personalis Reports Second Quarter Results and Recent Highlights

August 04, 2026

Halper Sadeh LLC is Investigating Whether UTZ, BLFS, FNWD, PSNL are Obtaining Fair Deals for their Shareholders

July 30, 2026

Halper Sadeh LLC is Investigating Whether FNWD and PSNL are Obtaining Fair Deals for their Shareholders

July 29, 2026

Halper Sadeh LLC is Investigating Whether LXP, FNWD, PSNL are Obtaining Fair Deals for their Shareholders

July 28, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Luxfer Holdings PLC (NYSE – LXFR), Finward Bancorp (Nasdaq – FNWD), Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR)

July 27, 2026

Halper Sadeh LLC is Investigating Whether UTZ, PSNL, LXP are Obtaining Fair Deals for their Shareholders

July 22, 2026

Personalis Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Personalis, Inc. - PSNL

July 21, 2026

From Kahn Swick & Foti, LLC

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)

July 21, 2026

PSNL Stock Alert: Halper Sadeh LLC is Investigating Whether Personalis, Inc. is Obtaining a Fair Price for Shareholders

July 20, 2026

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

July 20, 2026

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

July 14, 2026

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

June 09, 2026

Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors? ↗

June 04, 2026

Via The Motley Fool

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

June 02, 2026

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

May 26, 2026

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

May 20, 2026

Personalis to Participate in Upcoming Investor Events

May 14, 2026

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

May 13, 2026